Intellia: Copying Cathie Wood to Sell Too Soon

The 44% That Fell Short on Intellia Therapeutics

In March, a retail investor noticed that ARK Invest, Cathie Wood's fund, was accumulating more than 250,000 shares of Intellia Therapeutics, a biotech company focused on curative therapies. His reaction was not to study the financials or the project pipeline: he bought in with 3,000 euros at $9.83 per share and set a sell target at $20, just enough to double his cash. He didn't even care much about the business model.

Three weeks later, the position was in the green with a 44% profit. The temptation to take profits outweighed the initial plan, and the sale was executed well below the target. Then the predictable peine: the FDA lifted the clinical hold on the program, and the stock continued to rise without its original owner.

The Play That Mimics the Big Funds

The trade had an apparent logic: if a fund of ARK's caliber has bought, someone posting ideas on the internet won't do better. The problem, as the more skeptical analysis pointed out, is that institutional funds are required to diversify and in many of these positions they hedge with derivatives, something a retail investor cannot replicate. Moreover, Intellia's accounts didn't support the thesis: recurring losses and constant financing through debt and equity offerings.

That contrast between blind faith in the penny stock and the reality of the balance sheet is the core of the debate. Some sum it up with a maxim: penny stocks aren't studied, they're blindly trusted. And in the short term, that faith paid off: a 65% gain in a month, according to the informal price tracking done in the same circle.

The FDA, the Catalyst That Came Late

The underlying argument for buying Intellia was that the FDA would eventually lift the punishment imposed after a serious adverse event in a clinical trial. That ban had sunk the stock and left a bearish gap waiting to be filled. When the regulatory agency finally lifted the hold, the price not only regained momentum: technical analyses began to talk about a cup-with-handle pattern, with gap-fill targets in the $22-26 area.

Sellers who had taken profits were left watching. The patience missing in the first phase of the move was later found by those who held the position, although that doesn't turn the trade into a lesson in analysis: the bulk of the subsequent rally continued without fundamental support.

From Penny Stock to Commodities

The same playbook moved to other stocks. The trader who had led the entry into Intellia shifted to commodities and oil, with results he himself published as forecasts: Kosmos Energy +64%, Paladin Energy +31%, and Kistos +15% in a short period. As with any oracle, the selection of successes is cited with more enthusiasm than the failures.

The next suggestion circulating in the same circuit was Gossamer Bio, a phase 3 drug with an imminent binary event: either the data readout goes well or the stock collapses. All or nothing. It is the very definition of a biotech penny stock and a reminder that this type of trading admits no middle ground.

Intellia's earnings presentation was scheduled for February 19, a date that the more prudent flagged as the moment of truth for a stock that was rising on inertia. The date came and the price continued its path: when the FDA gave the green light, the rally resumed. The sarracena is not that selling at a 44% gain is a mistake. It's that in these stocks, the exit moment is decided by the market, not by a target scribbled on a napkin. And the data point that hurts the seller most: the gap was still there, waiting to be filled at $26.